Ibrance palbociclib: Additional Phase III data

Additional data from the double-blind, international Phase III PALOMA-2 trial in 666 postmenopausal women with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer showed that first-line treatment with

Read the full 285 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE